Vera Therapeutics Reports Q2 2026 Financial Results and FDA Approval of TRUTAKNA

Vera Therapeutics, Inc. reported significant financial results for the second quarter of 2026, reflecting ongoing investments in research and development and the recent FDA approval of its lead product, TRUTAKNA. The company recorded a net loss of $109.5 million for the three months ended June 30, 2026, compared to a net loss of $76.5 million for the same period in 2025. Total operating expenses increased to $112.5 million from $80.1 million year-over-year, driven primarily by a 139% rise in general and administrative expenses, which reached $52.4 million, largely due to increased personnel costs and preparations for the commercial launch of TRUTAKNA.

In terms of cash flow, Vera's cash, cash equivalents, and marketable securities totaled $499.2 million as of June 30, 2026, a decrease from $714.6 million at the end of 2025. The company utilized $206.8 million in operating activities during the first half of 2026, up from $109.2 million in the same period of 2025. This increase was attributed to higher research and development expenditures, which rose to $146.1 million for the six months ended June 30, 2026, compared to $99.5 million in the prior year. The increase in R&D spending was primarily due to higher employee compensation and milestone payments related to TRUTAKNA.

Strategically, Vera Therapeutics achieved a significant milestone with the accelerated approval of TRUTAKNA by the FDA on July 7, 2026, for the treatment of primary immunoglobulin A nephropathy (IgAN). This approval is based on positive interim results from the ongoing ORIGIN Phase 3 trial, which demonstrated a 46% reduction in proteinuria among treated patients. The company plans to submit a supplemental Biologics License Application for full approval later in 2026, contingent on the final efficacy analysis from the trial.

Operationally, Vera Therapeutics has focused on expanding its clinical pipeline, with TRUTAKNA being its only FDA-approved product to date. The company is also evaluating atacicept for additional autoimmune diseases and has plans to seek regulatory approvals in international markets. As of June 30, 2026, the company had an accumulated deficit of $991.4 million, reflecting its ongoing investment in product development and commercialization efforts. Looking ahead, Vera anticipates continued net losses as it scales operations and prepares for the commercial launch of TRUTAKNA, while also seeking additional funding to support its growth initiatives.